Quantitative proteomic and lipidomic analysis of LNCaP and C4-2 cell lines during CRPC progression

Prostate cancer (PCa) is one of the most common cancers diagnosed in men in the world. The majority of patients develop resistant to androgen deprovation therapy, leading to castration-resistant PCa (CRPC). CRPC have a poorer prognosis and developing metastasis compared to hormone-sensitive PCa. To chracterize for new regulators of progression from HSPC to CRPC, LNCaP and C4-2 cells were selected as HSPC and CRPC, respectively. A comparative assessment of proein expression characteristics between two cells may provide insight into the regulatory landscape of CRPC.